West Pharmaceutical Services (NYSE:WST) Issues FY 2025 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 6.000-6.200 for the period, compared to the consensus estimate of 7.430. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $3.0 billion.

West Pharmaceutical Services Stock Performance

NYSE:WST traded up $22.99 during midday trading on Friday, reaching $222.10. The stock had a trading volume of 2,529,295 shares, compared to its average volume of 676,799. The stock has a market capitalization of $16.08 billion, a P/E ratio of 32.93, a PEG ratio of 19.31 and a beta of 1.01. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.00 and a quick ratio of 2.23. West Pharmaceutical Services has a 1-year low of $197.01 and a 1-year high of $400.88. The firm’s fifty day simple moving average is $330.01 and its 200-day simple moving average is $314.33.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, February 13th. The medical instruments supplier reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.75 by $0.07. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. On average, equities research analysts forecast that West Pharmaceutical Services will post 6.67 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, February 11th. Stockholders of record on Friday, February 7th were given a $0.21 dividend. The ex-dividend date of this dividend was Friday, February 7th. This represents a $0.84 annualized dividend and a dividend yield of 0.38%. West Pharmaceutical Services’s dividend payout ratio is 12.46%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on WST shares. KeyCorp cut their target price on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a research note on Friday. Deutsche Bank Aktiengesellschaft upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 target price for the company in a research note on Friday. UBS Group raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and upped their price target for the company from $350.00 to $390.00 in a report on Thursday, December 12th. Wolfe Research began coverage on shares of West Pharmaceutical Services in a report on Friday, December 13th. They set a “peer perform” rating for the company. Finally, StockNews.com upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $344.00.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.